Expert Examines Emerging Biomarkers in NSCLC

Brandon Weckbaugh, MD, an oncology fellow at UMKC is interview on OncLive

The treatment landscape of non-small cell lung cancer (NSCLC) continues to expand with potential biomarkers that are under investigation, as well as novel agents that could potentially target them. What was once a major area of unmet need has experienced an explosion of new research, said Brandon Weckbaugh, MD. Read the interview.